Esperion Therapeutics Stock News

During the last session, Esperion Therapeutics Inc. (NASDAQ:ESPR)s traded shares were 6.98 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stocks price was $7.69, reflecting an intraday loss of -23.25% or -$2.33. The 52-week high for the ESPR share is $39.49, that puts it down How Will Esperion Therapeutics Inc. (NASDAQ: ESPR) Look After It Drops -413.52% From Its Highs? Read More »

Esperion Therapeutics, Inc. (ESPR) with the stream of -22.95% also noticed, India Gerdau S.A. (GGB) encountered a rapid change of 1.55% in the last hour of Wednesdays trading session. Esperion The post Sector Percentage Losers: Esperion Therapeutics, Inc. (NASDAQ:ESPR), Gerdau S.A. (NYSE:GGB) appeared first on Stocks Equity .

Man Group plc cut its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 50.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,778 shares of the biopharmaceutical companys stock after selling 14,248 shares during the quarter. Man Group plcs []

Investors need to pay close attention to Esperion Therapeutics (ESPR) stock based on the movements in the options market lately.

Maverick Capital Ltd. bought a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 44,992 shares of the biopharmaceutical companys stock, valued at approximately $952,000. Several other hedge funds have also bought and sold shares of ESPR. []

Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q3 2021 Results - Earnings Call Transcript

Esperion continues to struggle to get NEXLETOL and NEXLIZET off the launch pad as COVID-19 headwinds disrupt their commercial efforts. The lackluster launch and relentless cash burn has crushed the sh

Shareholders were displeased with the company's latest financial move.

The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) increased by over 6% during intraday trading today. This is why it happened.

Another day of strong earnings is pushing the broad markets higher across the board.

Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a year. What Happened: The Com

Shares of Esperion Therapeutics Inc. ESPR, -1.72% were down 1.5% in premarket trading on Monday after the company said it plans to reduce its workforce by 40%, citing the challenges of launching two c

– Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial –

ANN ARBOR, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future di